ASPH.F Stock Overview
A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ascentage Pharma Group International Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.69 |
| 52 Week High | HK$3.63 |
| 52 Week Low | HK$2.35 |
| Beta | 1.17 |
| 1 Month Change | 7.60% |
| 3 Month Change | 3.46% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -55.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| ASPH.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.6% | 2.6% | 1.6% |
| 1Y | n/a | 7.0% | 26.1% |
Return vs Industry: Insufficient data to determine how ASPH.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ASPH.F performed against the US Market.
Price Volatility
| ASPH.F volatility | |
|---|---|
| ASPH.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ASPH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ASPH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 583 | Dajun Yang | www.ascentage.cn |
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma.
Ascentage Pharma Group International Fundamentals Summary
| ASPH.F fundamental statistics | |
|---|---|
| Market cap | US$758.68m |
| Earnings (TTM) | -US$128.23m |
| Revenue (TTM) | US$30.75m |
24.7x
P/S Ratio-5.9x
P/E RatioIs ASPH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASPH.F income statement (TTM) | |
|---|---|
| Revenue | CN¥221.98m |
| Cost of Revenue | CN¥30.54m |
| Gross Profit | CN¥191.44m |
| Other Expenses | CN¥1.12b |
| Earnings | -CN¥925.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.25 |
| Gross Margin | 86.24% |
| Net Profit Margin | -416.98% |
| Debt/Equity Ratio | 2,510.1% |
How did ASPH.F perform over the long term?
See historical performance and comparison